A recent study revealed that STING agonists improved the effectiveness of CAR‐T‐cell therapy during the treatment of pancreatic cancer and melanoma, and codelivery of STING agonists and CAR‐T cells could effectively activate the immune response to eliminate tumor cells that were not recognized by adoptive metastatic lymphocytes. This evidence concerns the gene STING1 and familial pancreatic carcinoma.